Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,628

On the run up to Undoing Aging 2018, Nicola Bagalà from LEAF did an interview to learn a bit more about our foundation and the story of our involvement in life extension.

As our readers probably already know, from March 15 to March 17 this year, the Undoing Aging 2018 Conference will be held at the Umspannwerk Alexanderplatz in Berlin, Germany. The event is intended to bring together scientists working on repair-based therapies for aging as well as to give life sciences students—and anyone else who may be interested, really—an occasion to deepen their understanding of the current state of rejuvenation research.

Organised by the Forever Healthy Foundation and the SENS Research Foundation, the conference will feature eminent researchers among its many speakers, such as the director of the Wake Forest Institute for Regenerative Medicine, Dr. Anthony Atala; Dr. Kristen Fortney, who is an expert on computational drug discovery and aging biomarkers; Dr. Michael West, co-CEO of BioTime and founder of Geron Corporation; Dr. James Kirkland, a world-class expert on cellular senescence; and Dr. Vera Gorbunova, a pioneer of the comparative biology approach to the study of aging and co-director of the Rochester Aging Research Center. In addition to its scientific, educational, and networking value, UA2018 will no doubt greatly contribute to the popularisation of this area of research and help spread awareness, both about the problem represented by age-related diseases and the great opportunity we have to finally bring aging under comprehensive medical control within a relatively short time frame.

LEAF, naturally, will attend the event to keep you fully up to date, and our readers can expect extensive coverage during and following the event. Meanwhile, to whet your appetite, we caught up with Forever Healthy’s founder and CEO, Michael Greve, to learn a bit more about his foundation and the story of his involvement in life extension.

Read more

The Pentagon is hoping to tap into the incredible survival techniques of some of nature’s hardiest creatures to ‘slow biological time’ on the battlefield.

DARPA’s new program, dubbed Biostasis, aims to develop ways to buy extra time for wounded soldiers between the moment of injury and first medical treatment.

This window, known as the ‘golden hour,’ is a critical for survival – but in reality, it’s often far less than sixty minutes.

Read more

A research team composed of scientists from the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) and IBM Research has produced a new synthetic molecule that can target and kill five multidrug-resistant bacteria. This synthetic polymer was found to be non-toxic and could enable entirely new classes of therapeutics to address the growing problem of antibiotic-resistant superbugs.

The synthetic molecules are called guanidinium-functionalized polycarbonates and were found to be both biodegradable and non-toxic to human cells. Essentially, the positively-charged synthetic polymer enters a living body and binds specifically to certain bacteria cells by homing in on a microbial membrane’s related negative charge. Once attached to the bacteria, the polymer crosses the cell membrane and triggers the solidification of proteins and DNA in the cell, killing the bacteria.

Read more

Eye-drops that can repair the corneas and can improve the short and long sightedness have been developed by a team of Ophthalmologists at Shaare Zedek Medical Center and Bar-Ilan University’s Institute of Nanotechnology and Advanced Materials. The solution of nanoparticles called the ‘nanodrops’ was successfully tested on a pig’s cornea. Clinical trials are expected to be carried out later this year. If the clinical trials on humans are successful, it is expected that the need of eyeglasses will be eliminated.

The leader of the research team, Dr. David Smadja, said that the eye-drops can bring a revolution in ophthalmological and optometry treatment of patients who are suffering from myopia, hyperopia and other refractory conditions. The revolutionary breakthrough in the field was revealed by Dr. Smadja at Shaare Zedek’s second biennial research day, which was held at Steinberg Auditorium in Jerusalem. He said that the nano drops can also be used to replace multifocal lenses and allow people to see objects from different distances. Smadja said, “This is a new concept for correcting refractory problems.” However, he didn’t mention the times of applications which will replace the need for the glasses completely.

Read more

Battlefield medics frequently only have a brief window of opportunity to treat an injury before it’s fatal or causes permanent disabilities, and it’s frequently so fleeting that there’s not much they can do. DARPA is exploring an unusual solution to that problem: slow the biological processes to give medics more room to breathe. Its new Biostasis research program aims to bring cell activity to a near halt by using biochemicals that control energetics at the protein level. If animals like tardigrades and wood frogs can stabilize their cells to survive freezing and dehydration, similar techniques might offer more time to medics who want to treat wounds before a victim’s vital systems break down.

DARPA knows this won’t be easy. The trick is to slow down every cellular process at roughly the same rate — you can’t just pause a few while others run at full speed. You’d also have to minimize any damage when the cells return to their normal function.

The Biostasis program is still very young (its first day for answering proposers’ questions is March 20th), and DARPA isn’t expecting too much even from complete projects: it’s initially focusing on “benchtop” proofs of concept and will focus on real-world uses as the program nears its 5-year end. If it has any success, though, the program could prove to be a breakthrough for the medical field as a whole, not just in combat. Paramedics could buy themselves enough time to get a patient to hospital, and doctors could focus less on basic survival and more on full recoveries.

Read more

An international group of researchers has made a decisive step towards creating the technology to achieve simulations of brain-scale networks on future supercomputers of the exascale class. The breakthrough, published in Frontiers in Neuroinformatics, allows larger parts of the human brain to be represented, using the same amount of computer memory. Simultaneously, the new algorithm significantly speeds up brain simulations on existing supercomputers.

The human brain is an organ of incredible complexity, composed of 100 billion interconnected nerve cells. However, even with the help of the most powerful supercomputers available, it is currently impossible to simulate the exchange of neuronal signals in networks of this size.

“Since 2014, our software can simulate about one percent of the in the human brain with all their connections,” says Markus Diesmann, Director at the Jülich Institute of Neuroscience and Medicine (INM-6). In order to achieve this impressive feat, the software requires the entire main memory of petascale supercomputers, such as the K computer in Kobe and JUQUEEN in Jülich.

Read more

Before the 7.6 billion people alive today, demographers estimate that about 100 billion people lived and died. This is the reality of the human condition. Memento mori, as medieval Christians reflected—Remember that you have to die.

What if it didn’t have to be this way? There are, in fact, organisms whose bodies steadily and reliably replace cells with healthier cells, and whose tissues and organs self-repair and maintain their vigor. They’re called children. And there are cells in adults that divide indefinitely. They’re called cancer. What if there were a way to genetically re-engineer and chemically reprogram our cells to divide indefinitely like they do in children, and to continue this process throughout adulthood without becoming cancerous? Could we become immortal?

“I don’t want to achieve immortality through my work,” Woody Allen once said, “I want to achieve immortality through not dying. I don’t want to live on in the hearts of my countrymen; I want to live on in my apartment.” There are today well-funded groups of scientists who believe we can do just that. If these techno-dreamers succeed, would you want to live for 150 years? 300 years? Or even 500 years? I’m not talking about being brain-dead and bedridden on a morphine drip. I mean living a full, rich physical and mental life for centuries, possibly forever. Would you opt for immortality?

Read more

Israel-based BrainQ is a new neurotech startup hoping to take on brain-computer interface (BCI) companies like Braintree founder Bryan Johnson’s Kernel and Silicon Valley billionaire Elon Musk’s Neuralink.

It’s not clear yet what Musk’s startup intends to do with the computer chips it plans to put in our heads, but Johnson’s startup says it is focused on developing “technologies to understand and treat neurological diseases in new and exciting ways.”

Whatever sector each company goes for, both plan to insert chips in our brains to connect us to computers — the consequences of which could have dramatic effects on human memory, intelligence, communication and many other areas that could rocket humanity forward, should they work out.

Read more

The only difference is that in the case of the new technology Qure.ai is using, the artificial neuro network will be exposed to millions of cases instead of thousands. But can one trust a diagnosis made with the help of machines or AI? Human beings would typically trust another human being over a machine. But Warrier says that that is part and parcel of the diagnosis – human or artificial. Eighty-million chest X-rays happen in India every year, with radiology error rates for chest X-rays at 20–23 per cent. In fact, 19 per cent of lung nodules are missed! So even now if one goes to a trained radiologist, there are chances he can read or make a mistake in the diagnosis. But since the software runs through “millions” of scans instead of thousands as a human might, chances of an error are, in fact, lower. So chances of an error are, if anything, minimised. Secondly, as of now, Qure.ai is not producing a final report but developing a report that is ready for further analysis by a radiologist. “At locations across the country where radiologists are not available, this report can be the one that is physically available. It could go wrong but something is better than nothing,” argues Warrier. In cases where physicians disagree – often happens in cases like interstitial lung disease — the report produced through AI is “consistent and reproducible” and can be relied upon to arrive at a final conclusion. In India, Qure.ai has no competitors, but globally Zebra Medical Vision is the nearest competitor. The software has been adopted and deployed in five centres in Mumbai, Delhi, and Bengaluru. The company is also working with public health programmes in some countries. TB Reach has used it for processing TB cases (chest X-rays) from Nepal and Cameroon. Its solutions are being marketed in North America through its partners EnvoyAI (TeraRecon). According to Warrier, the global sales team of their parent company, Fractal Analytics, is helping them to reach out to health care providers and possible customers in the US and Europe. It may be early days yet, but if the technology and product prove as good as they claim, the benefits for patients will be felt for a long time to come.

Read more